RPO LLC’s AbCellera Biologics ABCL Stock Holding History

RPO LLC’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,937	Closed	-$61.3K	–	40
2024 Q4	$61.3K	Buy	+20,937	New	+$58.3K	0.06%	35

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

RPO LLC's ABCL Position: Q1 2025 in Review

RPO LLC sold out of AbCellera Biologics (ABCL) in Q1 2025, closing a stake of 20,937 shares — an estimated $61.3K sold.

RPO LLC first reported a position in ABCL in Q4 2024 and held it in 1 quarter. The position peaked at $61.3K in Q4 2024. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

RPO LLC reported no remaining AbCellera Biologics position as of Q1 2025 after selling out during the quarter.
RPO LLC sold 20,937 AbCellera Biologics shares in Q1 2025, an estimated $61.3K.
RPO LLC first reported a position in AbCellera Biologics in Q4 2024 and held it in 1 quarter.
RPO LLC's AbCellera Biologics position peaked at $61.3K in Q4 2024.
129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on RPO LLC's 13F filing for Q1 2025, filed 13 May 2025.